BioMedica

What BioMedica does

BioMedica is a privately held specialty pharmaceutical commercialization company headquartered in Munich, Germany, that distributes and in-licenses rare disease, oncology, hematology, hepatology, neurology, and ophthalmology therapies on behalf of biopharma originators across 30+ emerging and developed markets. Founded in 2019 by Oleg Parosin (formerly of Amgen, Johnson & Johnson, and UCB Pharma), the company operates a 'One-Stop Shop' model in which a single contract covers regulatory navigation, market access strategy, reimbursement, pharmacovigilance, and GDP/GMP-compliant distribution across CEE, CIS, Northern and Western Europe, Turkey, Israel, MENA, and APAC, delivered through a regional office network spanning Bratislava, Sofia, Tbilisi, Istanbul, Lviv, Warsaw, Bucharest, Astana, and Boston, with certified storage in the Czech Republic and Belgium.

BioMedica monetizes via distribution margins and in-licensing arrangements with no upfront payments and no long-term licensing rights required, allowing biopharma clients to retain upside while BioMedica earns on commercialized volume; it also enables day-2 post-FDA-approval access through Named Patient Programs. Its only publicly confirmed product-partnership to date is the exclusive distribution agreement with Santhera Pharmaceuticals for AGAMREE (vamorolone) in Duchenne muscular dystrophy, initially in Russia (October 2025) and subsequently expanded to Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan (July 2026). The underlying 'technology' is operational rather than software-based: a 50+ medical doctor and 10+ PhD medical/regulatory team, certified GDP/GMP infrastructure, and a KOL/Center of Excellence network across operational countries. The company is differentiated more by regulatory and distribution expertise, language coverage, and local relationships than by any proprietary platform.

The company is founder-led, with no disclosed external funding rounds, and is led by a senior team almost entirely drawn from large-pharma operators (Amgen, J&J, Pfizer, Merck, Novartis, Roche, Novo Nordisk, Sanofi, Genzyme), including dedicated VPs for each regional market and functional area (Quality, Regulatory, Pharmacovigilance, Legal, Compliance, Supply Chain). Growth has been organic and partnership-led, with a disclosed pipeline of USD 200M+ in six sourced deals since 2022, ABIA founding membership in 2026, and active APAC buildout signaled by a Partner-level APAC Senior Consultant role.

Name

BioMedica

Legal name

Biomedica GMBH

Website

https://biomedica.bio

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

BioMedica is a Munich-based specialty pharmaceutical company that distributes and in-licenses rare disease and specialty therapies for biopharma clients across 30+ emerging and developed markets via a single-contract commercialization model covering regulatory, market access, pharmacovigilance, and GDP/GMP-compliant distribution.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Distribution & Market Access Services

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

akta.pro secondary industry

Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Rare disease commercialization
• Pharmaceutical market access
• Named patient programs
• Orphan drug distribution
• Emerging market entry

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Distribution and In-Licensing Services: BioMedica generates revenue through distribution and in-licensing agreements with biopharma companies. They handle market access, regulatory navigation, and commercialization in emerging markets in exchange for distribution margins or licensing arrangements. The model is flexible, avoiding upfront payments and long-term contracts, allowing clients to retain control and full upside potential while BioMedica earns competitive margins on commercialization activities.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

BioMedica is a pharmaceutical commercialization company that partners with biopharma companies to bring rare disease, innovative, and breakthrough therapies to patients in underserved and emerging markets. Through distribution and in-licensing, the company delivers market access strategy, regulatory compliance, Named Patient Programs (NPP), Early Access Programs (EAP), reimbursement optimization, distribution management, and pharmacovigilance services across 30+ countries. Its current commercial product is AGAMREE® (vamorolone), a novel dissociative anti-inflammatory drug for Duchenne muscular dystrophy, distributed under an exclusive agreement with Santhera Pharmaceuticals.

Product overview

BioMedica is a pharmaceutical company that specializes in the commercialization of rare disease, innovative, and breakthrough therapies across underserved and emerging markets. The company's core offering is a comprehensive suite of market access, regulatory, and distribution services — spanning early access and named patient programs (NPP), through to commercial distribution — delivered via a 'One-Stop Shop' model covering 30+ countries across CEE, CIS, Northern/Western Europe, MENA, and APAC. BioMedica's primary pharmaceutical product under distribution is AGAMREE® (vamorolone), a novel dissociative anti-inflammatory treatment for Duchenne muscular dystrophy (DMD), partnered with Santhera Pharmaceuticals. The portfolio is organized around six therapeutic areas: rare diseases, oncology, hematology, hepatology, neurology, and ophthalmology. Services include strategic guidance for market access pathways, regulatory compliance, tailored healthcare solutions, and personalized patient care, with global offices in Germany, the US, Bulgaria, UAE, Georgia, Kazakhstan, Slovakia, Singapore, Turkey, Canada, and Ukraine.

Differentiator

Problem solved

Functional benefit

Products and services

• AGAMREE® (Vamorolone) A novel dissociative anti-inflammatory drug for the treatment of Duchenne muscular dystrophy (DMD) in pediatric patients. It binds to the same receptor as glucocorticoids while modifying downstream activity and is not a substrate for 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes, offering a mechanism that dissociates efficacy from typical corticosteroid-associated safety concerns. Distributed by BioMedica under an exclusive agreement with Santhera Pharmaceuticals.
• One-Stop Shop Rare Disease Commercialization Services A comprehensive suite of commercialization services covering market access strategy, regulatory compliance, Named Patient Programs (NPP), Early Access Programs (EAP), distribution management, reimbursement optimization, and pharmacovigilance delivered under a single contract across 30+ countries. Services span CEE, CIS, Northern & Western Europe, Turkey, Israel, and MENA. Targeted at biopharma companies with late-stage to commercial-phase rare disease therapies seeking emerging market entry.
• Named Patient Program (NPP) and Early Access Program (EAP) Distribution Enables rapid patient access to FDA/EMA-approved rare disease therapies in emerging markets before full local regulatory approval, with launches feasible as early as day 2 post-FDA approval. Includes program design, regulatory navigation, distribution, and pharmacovigilance through BioMedica's GDP-compliant certified storage facilities in Czech Republic and Belgium.

Quantifiable outcome

• 100%+ annual growth for clients compared to existing markets
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Santhera PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 15 October 2025BioMedica signed an exclusive distribution agreement with Santhera Pharmaceuticals (SIX: SANN) for AGAMREE® (vamorolone) in Russia (October 2025), covering DMD treatment for patients aged 4 and older. The agreement was subsequently expanded (July 2026) to include Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan, covering DMD patients aged 2 and older. Approximately 1,400 DMD patients in Russia and 2,000 in the additional five countries are targeted. Distribution began in Q1 2026 in Russia. AGAMREE is approved by FDA, European Commission, MHRA, Swissmedic, NMPA, Hong Kong DoH, and Health Canada.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Medison Pharma: Medison Pharma is a specialty pharmaceutical commercialization partner offering distribution and market-access services for innovative therapies across CEE, Israel, and additional emerging markets. It is directly comparable to BioMedica in both business model (in-licensing + multi-market distribution) and target client base (biopharma companies seeking rapid emerging-market entry), and is referenced via BioMedica's COO/CMO Ludovit Jurecek's prior GM role there.
• Swixx BioPharma: Swixx BioPharma is a specialty biopharma commercialization platform that commercializes innovative therapeutics across CEE, MENA, and APAC for global biopharma clients. It is a direct peer to BioMedica given its matching in-licensing model, rare/specialty focus, and overlapping geographic footprint.

Broad incumbents

• Hikma Pharmaceuticals: Hikma Pharmaceuticals is a UK-listed multinational specialty pharmaceutical company with a strong emerging-markets presence in MENA and a branded/specialty generics portfolio. It is a broad incumbent peer to BioMedica: it operates a much larger portfolio across many of the same geographies but does not focus on rare-disease in-licensing for biopharma clients.
• Stada Arzneimittel: Stada is a European specialty pharmaceutical company with a broad generics, specialty, and consumer health portfolio and significant distribution across CEE and CIS markets. It overlaps with BioMedica in CEE/CIS distribution infrastructure and specialty focus, but operates as a product-owning manufacturer rather than a third-party commercialization partner.
• Sobi (Swedish Orphan Biovitrum): Sobi is a global rare-disease specialty biopharma company focused on immunology, genetics, and metabolic diseases. It is a broad incumbent peer to BioMedica given its rare-disease specialization and overlapping therapeutic areas (hematology, neurology), though Sobi owns and develops its own products rather than serving as a distribution partner for third-party biopharma.
• Viatris: Viatris is a global pharmaceutical company with a broad branded, generic, and biosimilars portfolio and meaningful presence in emerging markets including CEE and CIS. It is a broad incumbent comparable to BioMedica in commercial footprint across many of the same regions but operates on a much larger, product-owning scale.
• Recordati: Recordati is an Italian specialty pharmaceutical group with a focus on rare diseases and treatments for niche therapeutic areas across Europe and select emerging markets. It is a broad incumbent peer to BioMedica given its European specialty/rare-disease orientation, though it operates as a product originator rather than as a third-party commercialization platform.

Regional players

• A. Menarini: A. Menarini is an Italian privately-held pharmaceutical company with a broad branded specialty portfolio and a strong commercial presence across CEE, CIS, and Mediterranean markets. It overlaps with BioMedica geographically but is a regional product-owning manufacturer rather than a multi-market in-licensing commercialization partner.
• Egis Pharmaceuticals: Egis Pharmaceuticals is a Hungarian-headquartered generic and specialty pharmaceutical manufacturer with deep CEE distribution. It is a regional peer to BioMedica via overlapping CEE/CIS footprint and specialty pharma activity, though it operates as an originator manufacturer rather than as an in-licensing commercialization partner.
• Almirall: Almirall is a Spanish specialty pharmaceutical company focused on dermatology and other specialty therapeutic areas across Europe. It is a regional peer to BioMedica given its European specialty-pharma orientation and similar therapeutic-area breadth, but is a product-owning manufacturer rather than a multi-market third-party commercialization platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biomedica-gmbh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMedica